Serious adverse events. Outcome assessed on day 42 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes serious adverse events. Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Relapse · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes treatment response: relapse (day 42). Outcome assessed on day 42 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Microbiological response: eradicated. Outcome assessed on day 21 · bronchiectasis
It is very uncertain whether oral + inhaled dual therapy changes microbiological response: eradicated. Outcome assessed on day 21 compared with oral monotherapy (very low certainty).
1 finding from 1 review
Hospital admissions · bronchiectasis
1 finding from 1 review
Death · bronchiectasis
1 finding from 1 review
Quality of life · bronchiectasis
1 finding from 1 review
Health‐related quality of life · people with non‐cystic fibrosis bronchiectasis
2 findings from 1 review
Exacerbations requiring antibiotics · people with non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events: mortality · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Hospital admissions · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Lung function · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Self‐efficacy · people with non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Costs · people with non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response rate ‐ improvement in sputum purulence · adults with bronchiectasis
It is very uncertain whether polymyxins changes response rate ‐ improvement in sputum purulence compared with aminoglycosides (very low certainty).
1 finding from 1 review
Response rate ‐ P aeruginosa eradication · adults with bronchiectasis
It is very uncertain whether polymyxins changes response rate ‐ P aeruginosa eradication compared with aminoglycosides (very low certainty).
1 finding from 1 review
Deaths · adults with bronchiectasis
1 finding from 1 review
Quality of life · adults with bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review